Silex milestones approach
About the author:
- Author name:
- By Scott Power
- Job title:
- Senior Analyst
- Date posted:
- 02 October 2013, 12:24 PM
- Sectors Covered:
- Healthcare, Life Sciences
Silex's share price is starting to recover, triggered by an improving Uranium price and potentially positive near-term milestone.
The key milestone is a decision from the US Dept of Energy (DOE) on whether they will agree to use the Silex technology to enrich high assay tails at the site in Paducah, Kentucky (a first generation enrichment plant which was closed down in May). A decision from the DOE is expected in the next few months.
If a positive decision is made the share price will re-rate quickly to our Price Target of A$4.14.
Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.
-
Print this page
-
Copy Link